Navin Rajagopalan, MD
Advanced Heart Failure and Transplant Cardiology · Lexington, KYNPI 1215148234
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Abbott at 40.5% of the total. 2025 is the largest year on record at $1,447, 2.5 times the $570 reported in 2019.
Across 104 payments — averaging $57.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AstraZeneca$447
- Cvrx, Inc.$441
- Abiomed$410
- Impulse Dynamics (USA) Inc.$271
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$195
- plus $2K from 22 others
Across 7 payments — averaging $2405.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$17K
What the payments were for
- Consulting fees$5639%
- Food & beverage$5,41591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 30 | $2,420 |
| AstraZeneca | 4 | $447 |
| Cvrx, Inc. | 9 | $441 |
| Abiomed | 3 | $410 |
| Impulse Dynamics (USA) Inc. | 2 | $271 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $195 |
| Merck | 7 | $193 |
| Cardiac Dimensions, Inc. | 2 | $168 |
| Pfizer | 8 | $160 |
| Bridgebio Pharma, Inc. | 1 | $147 |
| Boston Scientific | 3 | $142 |
| Lexicon Pharmaceuticals, Inc. | 2 | $133 |
| Amgen | 3 | $128 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Medtronic | 1 | $114 |
| Nuwellis, Inc. | 1 | $97 |
| Novartis | 6 | $96 |
| Philips North America LLC | 1 | $63 |
| Akcea Therapeutics, Inc. | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 3 | $43 |
| Scpharmaceuticals Inc. | 1 | $38 |
| Atricure, Inc. | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$827
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$725
- OPTIMIZER$542
- Impella$410
- Barostim Neo System$252
- FARXIGA$236
- Attruby$147
- Inpefa$120
- CAMZYOS$119
- LOKELMA$116
- HeartWare HVAD$114
- Repatha$106
- GENERAL TACHY$101
How this compares
Too few advanced heart failure and transplant cardiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 243 | $263,137 |
| FarxigaDapagliflozin Propanediol | 134 | $127,158 |
| JardianceEmpagliflozin | 104 | $107,676 |
| EliquisApixaban | 64 | $57,965 |
| OzempicSemaglutide | 25 | $23,977 |
| Bumetanide | 48 | $1,894 |
| Metoprolol Succinate | 164 | $1,867 |
| Eplerenone | 30 | $1,286 |
| Spironolactone | 162 | $790 |
| Carvedilol | 81 | $492 |
| Torsemide | 50 | $473 |
| Ranolazine ErRanolazine | 11 | $341 |
| Atorvastatin Calcium | 41 | $290 |
| Potassium Chloride | 19 | $249 |
| Lisinopril | 14 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $96 | $263,137243 claims |
| AstraZenecaFarxiga | $447 | $127,158134 claims |
| PfizerEliquis | $160 | $57,96564 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Lexington
- Sonu AbrahamLexington$13K
- Marciano LeeLexington$11K
- Andrew KolodziejLexington$7K
- Maya IgnaszewskiLexington$6K
- Paul AnayaLexington$194
- Timothy RaymondFt Wright$88K
- Chioma ObiokoyeLouisville$14K
- Hareeprasad VongooruEdgewood$8K
- Amaninderapal GhotraEdgewood$8K
- Keerthy NarisettyEdgewood$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.